Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Humanin (HN) is a anti-aging peptide, at the preclinical stage in the published literature. Mitochondria-derived peptide with cytoprotective and anti-apoptotic effects. Natural levels decline with age.
Mitochondria-derived peptide with cytoprotective and anti-apoptotic effects. Natural levels decline with age.
| Research Status | Preclinical |
|---|---|
| Half-Life | Unknown |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 1-5 mg |
Binds to multiple receptors including IGFBP-3 and BAX, preventing apoptosis and protecting cells from stress.
Mitochondria-derived peptide with cytoprotective and anti-apoptotic effects. Natural levels decline with age.
Binds to multiple receptors including IGFBP-3 and BAX, preventing apoptosis and protecting cells from stress.
Humanin is at the following stage in the published literature: Preclinical. All information is for research and educational purposes only.
Reported half-life: Unknown.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.